Eli Lilly and Company Stock Analysis: Q2 Earnings Beat Meets Intraday Reversal

Eli Lilly and Company reported strong Q2 2026 earnings, driven by GLP-1 products, and raised full-year guidance. Despite this positive fundamental news, the stock experienced a sharp intraday reversal, closing significantly lower after an initial spike, forming a rejection candle on the daily chart. This analysis explores the technical indicators and key levels to watch, highlighting the conflict between robust fundamentals and weakened short-term technical momentum, suggesting a transitional phase for the stock.